177 Lu-DOTATATE Uptake in the Lungs of a Patient With COVID-19 Pneumonia.
Clin Nucl Med
; 49(9): 877-878, 2024 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-38968595
ABSTRACT
ABSTRACT A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177 Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177 Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177 Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organometallic Compounds
/
Pneumonia, Viral
/
Octreotide
/
COVID-19
/
Lung
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
Clin Nucl Med
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: